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Abstract
We used an approach that we term ancestry-shift refinement mapping to investigate an association, originally discovered in
a GWAS of a Chinese population, between rs2046210[T] and breast cancer susceptibility. The locus is on 6q25.1 in proximity
to the C6orf97 and estrogen receptor a (ESR1) genes. We identified a panel of SNPs that are correlated with rs2046210 in
Chinese, but not necessarily so in other ancestral populations, and genotyped them in breast cancer case:control samples of
Asian, European, and African origin, a total of 10,176 cases and 13,286 controls. We found that rs2046210[T] does not confer
substantial risk of breast cancer in Europeans and Africans (OR=1.04, P=0.099, and OR=0.98, P=0.77, respectively). Rather,
in those ancestries, an association signal arises from a group of less common SNPs typified by rs9397435. The rs9397435[G]
allele was found to confer risk of breast cancer in European (OR=1.15, P=1.2610
23), African (OR=1.35, P=0.014), and
Asian (OR=1.23, P=2.9610
24) population samples. Combined over all ancestries, the OR was 1.19 (P=3.9610
27), was
without significant heterogeneity between ancestries (Phet=0.36) and the SNP fully accounted for the association signal in
each ancestry. Haplotypes bearing rs9397435[G] are well tagged by rs2046210[T] only in Asians. The rs9397435[G] allele
showed associations with both estrogen receptor positive and estrogen receptor negative breast cancer. Using early-draft
data from the 1,000 Genomes project, we found that the risk allele of a novel SNP (rs77275268), which is closely correlated
with rs9397435, disrupts a partially methylated CpG sequence within a known CTCF binding site. These studies demonstrate
that shifting the analysis among ancestral populations can provide valuable resolution in association mapping.
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Introduction
Recent genome-wide association studies (GWAS) have identi-
fied a number of new susceptibility loci for breast cancer and other
cancers [1–5]. In most studies, strong evidence has been obtained
for risk association in one particular ancestral group, usually
Europeans. SNPs represented on microarray chips used in GWAS
protocols are selected in part because they each tag a group of
correlated, ungenotyped SNPs through linkage disequilibrium
(LD). There is no particular expectation that a SNP identified in a
GWAS is a pathogenic, causative variant. Rather, it is more likely
that such a SNP is in LD with a pathogenic variant (or a set of
pathogenic variants, see Discussion) that is not genotyped directly. If
the analysis is moved to a population with different ancestry, then
the tagging relationship between the SNP and the pathogenic
variant may be disrupted as a result of the difference in LD
between ancestral populations [6].
There are two main motivations for identifying SNPs whose
property of tagging a pathogenic variant is not disrupted by
changes in LD resulting from a shift to another ancestral
population. Firstly, one might wish to test for risk arising from
the susceptibility locus in a population of different ancestry, or
indeed to determine whether a similar pathogenic variant exists at
the susceptibility locus in another ancestral group. Secondly, by
moving the analysis into another ancestral population, it might be
possible to separate SNPs that are so highly correlated in the
original population that their risk associations are indistinguish-
able. This could aid in the identification of SNPs that are most
strongly correlated with the pathogenic variant, and move the
analysis closer to the identification of the pathogenic variant itself.
This approach, which we term ancestry-shift refinement mapping,
has been formalized and used previously [5,7–12]. However the
interpretation has sometimes been limited by low power in the
target ancestral populations or the lack of comprehensive
genotypes.
The estrogen receptor a (ESR1) locus has been a focus of
attention because of the roles of estrogen in risk of breast cancer,
osteoporosis and other conditions. Moreover, estrogen receptor
(ER) expression in breast tumours is of prime prognostic
importance [13]. Many investigations have been conducted
searching for risk associations with sequence variants in ESR1,
generally with equivocal results [14]. Comprehensive tag-SNP and
meta-analyses found little evidence of breast cancer risk variants in
the ESR1 gene itself [15,16]. Recently, a GWAS conducted in a
large sample from the Shanghai Breast Cancer Study identified an
association between rs2046210 and breast cancer in Chinese [1].
SNP rs2046210 is located 180kb 59 to the major ESR1 transcript
initiation sites (and 63kb 59 to the start site of ESR1 isoform 4). The
SNP is about 6kb downstream of the 39 end of C6orf97, a RefSeq
gene of unknown function (Figure 1, upper panel). The LD
structure of the region is shown in Figure S1. Zheng et al. [1]
reported that rs2046210 also confers risk of breast cancer in a
population of European ancestry (allelic OR=1.15, P=0.01).
However, the evidence from the publically available CGEMS
dataset is more equivocal [17]. We estimated from the CGEMS
data an allelic OR of 1.09, P=0.25 for rs6900157, the best tagger
(r
2=0.93 in HapMap CEU) of rs2046210 on the CGEMS
Illumina chip. Our own breast cancer GWAS dataset from 1,982
patients and 35,895 controls [4,5] provided no evidence of a risk
associated with rs6900157 in Europeans (allelic OR=1.04,
P=0.36).
We suspected that the reason for our failure to replicate the
Zheng et al. signal in Europeans could be because the LD
relationship between the reported SNP rs2046210 and the
pathogenic variant(s) might differ between Chinese and Europe-
ans. Here we show that this is indeed the case. By studying a large
class of SNPs that are highly correlated in Chinese but not
necessarily so in ancestral Europeans and Africans, we were able
to identify a class of less common SNPs (6–7% minor allele
frequency [MAF] in Europeans and 1–6% in Africans) that are
associated with breast cancer risk in non-Asian populations. The
most strongly associated SNP, rs9397435, fully accounts for the
association in all three ancestries.
Results
To search for SNPs that might detect the C6orf97-ESR1 signal in
non-Asian ancestries, we first identified 36 SNPs that are well
correlated (r
2$0.65) with rs2046210 in the Chinese, using the
HapMap CHB dataset (Figure 1, lower panel, Figure S2). Then,
using the HapMap CEU dataset, we observed the pattern of
correlations between these SNPs in a population of European
ancestry. The dendrogram in Figure 2A shows a hierarchical
clustering of the 37 SNPs, based on their r
2 values. We defined
equivalence classes as sets of SNPs (or branches of the
Author Summary
In genome-wide association studies of disease suscepti-
bility, there is no particular expectation that a genotyped
SNP showing an association is itself a pathogenic variant.
Rather, it is more likely that a SNP giving a signal does so
because it is in linkage disequilibrium (LD) with a
pathogenic variant. When the analysis is shifted to a
population of another ancestry, the tagging relationship
between the genotyped SNP and the pathogenic variant
may be disrupted, due to differing patterns of LD between
populations. Thus, it is not straightforward to determine
whether a susceptibility locus identified in one ancestral
population is also associated with risk in another.
Moreover, the differing patterns of LD between ancestral
populations can be used to gain resolution in genetic
mapping. We refer to this approach as ancestry-shift
refinement mapping. Here, we apply it to a breast cancer
risk variant near the estrogen receptor a gene that was
initially described in a Chinese population. We show that
the tagging relationship between the originally described
SNP rs2046210 and the pathogenic variant(s) is not
maintained in Europeans and Africans. We identify a SNP,
rs9397435, that is associated with breast cancer risk in
populations of Asian, European, and African ancestry.
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2$0.8 in CEU. We
then selected a set of SNPs for genotyping such that at least one
SNP in each equivalence class was included. These SNPs are
highlighted in Figure 2A. We put in some redundant SNPs, partly
to cover additional class fractionation in Africans (see below), and
partly in order to examine two non-synonymous coding SNPs in
the C6orof97 gene: V604I (rs6929137) and V683I (rs3734804).
Single track Centaurus [18] assays were generated for the selected
SNPs and validated by typing them in the HapMap CEU, CHB/
JPT, and YRI samples.
We then typed the selected SNPs in a series of breast cancer
case:control samples of European ancestry from Iceland, the
Netherlands, Spain, Sweden, and U.S.A.; a total of 7,899 breast
cancer cases and 11,234 controls. Details of the sample sets are
given in Table S1. In addition, we typed the selected SNPs in a
sample of 1,126 breast cancer cases and 1,118 controls of Chinese
ancestry from Taiwan. The results are summarized in Table 1 and
individual results for each sample set are given in Table S2. We
used a likelihood approach to ensure that the same individuals
were tested for each SNP, so that the P values for the different
SNPs could be compared directly (see Materials and Methods). The
results from the Taiwanese sample confirmed the association
between breast cancer risk and the key SNP rs2046210
(OR=1.24, P=4.3610
24) that was previously reported in
Shanghai Chinese [1]. We also obtained significant signals for a
range of SNPs that are highly correlated with rs2046210 in the
Taiwanese. However, in the combined European ancestry
populations, it was evident that rs2046210 confers little or no risk
of breast cancer (OR=1.04, P=0.099, Table 1), despite the fact
that the MAF of rs2046210 is almost the same in Asians and
Europeans. However, we observed significant risk estimates in
Europeans arising from a group of SNPs with MAFs in the 6–7%
range, tagged by rs9397435, rs12662670, rs12665607, rs9383589
and rs3734805 (Table 1). The association P values for these SNPs
remained significant if we applied Bonferroni correction for the
number of European equivalence classes tested (significance
threshold P=0.05 divided by 7 classes=0.007). These SNPs are
highly or moderately correlated with each other in Europeans,
judging from the HapMap data (Figure 2A) and the observed data
from the genotyped samples (Figure S3). The strongest signal came
from rs9383589[G] (OR=1.15, P=6.2610
24). Thus, if the
pathogenic variant that is present in Chinese is also present in
Europeans, then in Europeans it appears to be tagged better by
rs9383589 than by rs2046210. There was no substantial signal
detected from either of the two coding variants in C6orf97
(rs6929137 and rs3734804), ruling them out as causative variants
(Table 1). It should be noted that this analysis does not represent a
comprehensive scan for risk variants at the locus in Europeans, but
is limited to SNPs that are strongly associated with the signal in
Asians.
We then examined how the SNPs in the European 6–7% MAF
classes were correlated in Yorubas, using the HapMap data. In
YRI, the SNPs split into five separate equivalence classes, with
MAFs ranging from about 6% (for the class tagged by rs9397435)
Figure 1. Overview of the C6orf97-ESR1 breast cancer susceptibility locus. The upper panel shows a view of the genomic region of
chromosome 6, nucleotides 151,930,000–152,200,000 taken from the UCSC browser Build 36 assembly (hg18). The C6orf97 gene and the four RefSeq
isoforms of ESR1 are shown. Below them is a histogram of the local recombination rates calculated as previously described [38] from HapMap phase II
release 22 data. Below that is a track showing the locations of the SNPs that are correlated (r
2$0.65) with rs2046210 in Han Chinese (‘‘Eq Class SNPs’’).
The lower panel shows a zoomed view of the region nucleotides 151,960,548–152,013,381, containing the Eq Class SNPs. RefSeq genes and
recombination rates are as in the upper panel.
doi:10.1371/journal.pgen.1001029.g001
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typed these five SNPs in a sample of 851 breast cancer patients
and 781 controls from Ibadan, Nigeria. We also included the key
SNP rs2046210 and rs6929137, the V604I coding variant that is
closely correlated with rs2046210 in Chinese and Europeans but
not in Yorubas (Figure 2B). To confirm the associations observed
in the Nigerians, we also typed the SNPs in a small set of African
American breast cancer patients and controls from the Chicago
area. Combined results from the two sample sets are shown in
Table 1 and data from each of the two sets separately are shown in
Table S2. Even though they are in different equivalence classes in
Africans, nominally significant ORs were observed for rs9397435,
rs12662670, rs12665607, and rs9383589 (Table 1). Inspection of
the results from the Nigerians separately (Table 2, Table S2) and
of the LD patterns in the data from the Nigerians and African
Americans (Figure S3) did not suggest that the lack of resolution
between these SNPs could be explained by European admixture in
the African American samples. Neither the key SNP rs2046210
nor the coding variant rs6929137 showed any association with
breast cancer risk in the African ancestry samples, hence they are
unlikely to be causative or closely correlated with the causative
variant. This is in agreement with Zheng et al. who previously
reported that they were unable to see an association between
rs2046210 or rs6929137 and risk in a sample of 810 African
American breast cancer cases and 1,784 controls [9].
If a pathogenic variant is present in all three ancestries, then it
might be expected to have a similar effect in all populations [8,19].
A variant that is in strong LD with a pathogenic variant could also
show similar properties, if the LD is maintained in different
ancestral populations. Such variants are likely to show the
strongest overall disease association when combined over all
ancestries. In order to assess the genotyped variants for these
characteristics, we used the Mantel-Haenszel model to obtain
combined OR estimates and P values for the SNPs that had been
typed in all three ancestral populations. The strongest breast
cancer association overall, both in terms of OR and P value, was
with rs9397435[G], a member of the European 6–7% MAF class,
giving an OR of 1.19 and P=3.90610
27 (Table 1). The other
four SNPs in the European 6–7% MAF class and 1–6% African
MAF classes also showed substantial signals combined over all
three ancestries. None of these five SNPs showed significant
heterogeneity in OR estimates over the three ancestries (Table S3).
However, all of the SNPs outside these classes (rs6929137 being an
exception) showed significant heterogeneity between all three
Figure 2. Dendrograms showing r
2 relationships between C6orf97-ESR1 SNPs in Europeans (CEU) and Yoruba Africans (YRI). On the
left are listed the 37 SNPs that are correlated with an r
2$0.65 with rs2046210 (arrowed) in HapMap Han Chinese (CHB). In panel (a) the SNPs are
arranged in a hierarchical cluster dendrogram based on the r
2 values between them in the HapMap CEU sample of a European ancestry population.
SNPs that were selected for genotyping are highlighted. SNPs indicated by *** are present on the Illumina Human Hap300 or HumanCNV370 chips
used in the Icelandic GWAS. Panel (b) shows the same SNPs in a dendrogram based on r
2 values from Yoruba Africans (HapMap YRI). Data are derived
from HapMap Phase II release 23a.
doi:10.1371/journal.pgen.1001029.g002
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effects are not consistent in all ancestries (Table 1, Table S3).
We then investigated whether the SNP with the strongest
overall association could account for the signals observed in all
three ancestries. In a multivariate analysis, no SNP in any
ancestral group retained a significant at-risk signal when adjusted
for the effect of rs9397435 (Table 2). Thus there is no evidence for
an association signal in any of the ancestries that is not captured by
rs9397435. In Europeans, rs9397435 retained significant ORs
when adjusted for the effects of rs2046210, rs6929137, and
marginally when adjusted for rs12662670 (Table 2). No significant
ORadj was observed when rs9397435 was adjusted for rs12665607,
Table 1. Association of C6orf97/ESR1 SNPs with breast cancer in populations of different ancestries.
SNP Allele Ancestry
a Frequency in Controls
b OR 95% CI P
rs9383932 G Asian 0.378 1.25 (1.11, 1.41) 2.9610
24
European 0.132 1.06 (1.00, 1.13) 0.066
rs9397435 G Asian 0.326 1.23 (1.09, 1.40) 8.0610
24
European 0.063 1.15 (1.06, 1.25) 1.2610
23
African & African American 0.063 1.35 (1.06, 1.71) 0.014
All Ancestries NA 1.19 (1.11, 1.27) 3.9610
27
rs12662670 G Asian 0.343 1.22 (1.07, 1.39) 2.5610
23
European 0.071 1.12 (1.03, 1.21) 6.4610
23
African & African American 0.027 1.54 (1.06, 2.23) 0.022
All Ancestries NA 1.16 (1.08, 1.24) 1.9610
25
rs12665607 A Asian 0.323 1.24 (1.10, 1.40) 6.2610
24
European 0.072 1.14 (1.05, 1.23) 1.1610
23
African & African American 0.010 1.94 (1.14, 3.30) 0.015
All Ancestries NA 1.18 (1.10, 1.26) 1.2610
26
rs9383589 G Asian 0.323 1.20 (1.06, 1.36) 4.2610
23
European 0.070 1.15 (1.06, 1.25) 6.2610
24
African & African American 0.016 1.61 (1.05, 2.48) 0.029
All Ancestries NA 1.17 (1.10, 1.25) 2.5610
26
rs3734805 C Asian 0.324 1.22 (1.07, 1.37) 2.0610
23
European 0.072 1.13 (1.05, 1.23) 1.8610
23
African & African American 0.028 1.27 (0.91, 1.78) 0.16
All Ancestries NA 1.16 (1.09, 1.23) 7.8610
26
rs6929137 A Asian 0.348 1.15 (1.02, 1.30) 0.025
European 0.316 1.04 (0.99, 1.09) 0.082
African & African American 0.538 1.02 (0.89, 1.16) 0.81
All Ancestries NA 1.05 (1.01, 1.09) 0.017
rs2046210 T
c Asian 0.363 1.24 (1.10, 1.40) 4.3610
24
European 0.337 1.04 (0.99, 1.08) 0.099
African & African American 0.716 0.98 (0.86, 1.11) 0.77
All Ancestries NA 1.06
d (1.01, 1.10) 9.8610
23
rs7752591 A Asian 0.421 1.25 (1.11, 1.40) 3.0610
24
European 0.495 1.03 (0.99, 1.07) 0.16
rs3734804 A Asian 0.422 1.21 (1.08, 1.37) 1.4610
23
European 0.474 1.00 (0.95, 1.05) 0.97
rs6932260 C Asian 0.422 1.23 (1.09, 1.38) 7.7610
24
European 0.474 1.00 (0.95, 1.05) 0.96
rs852003 A Asian 0.424 1.26 (1.12, 1.42) 1.2610
24
European 0.556 1.04 (0.99, 1.08) 0.11
aNumbers of Cases and Controls are Asian: 1,126 cases and 1,118 controls; European: 7,899 cases and 11,234 controls; African & African American: 1,151 cases and 934
controls; All Ancestries: 10,176 cases and 13,286 controls. Details of the sample sets for each ancestry are in Table S1 and association data for each individual sample set
are in Table S2.
bQuoted Frequency in controls is the simple arithmetic average of all European sample sets for European Ancestry and the frequency in Nigerians for the African &
African American Ancestry. NA, not applicable.
cThis allele is coded as ‘‘A’’ in Zheng et al. [1].
dSignificant heterogeneity in risk estimates for different ancestries, see Table S3.
doi:10.1371/journal.pgen.1001029.t001
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based on the available power, no tested SNP is more closely
correlated with the causative variant in Europeans than
rs9397435. However rs12665607, rs9383589, and rs3734805 are
similarly correlated with the causative variant and cannot be
distinguished from rs9397435 in this respect. Data from the
Nigerians support the exclusion of rs2046210, rs6929137, and the
tentative exclusion of rs12662670 from being the most strongly
correlated with the causative variant but no additional resolution
was achieved, the power again being limited by the sample size
and low frequencies of the variants (Table 2). Data from the
Taiwanese reconfirmed that little or no resolution is available
Table 2. Conditional analysis of rs9397435 association with breast cancer in European, Nigerian, and Taiwanese population
samples.
Population Sample Primary SNP Allele
Frequency in
Controls Unadjusted Adjusted for SNP Adjusted
OR P ORadj Presidual
Combined European rs9397435 G 0.063 1.15 1.2610
23 rs9383932 1.16 4.2610
23
" rs9397435 G " " " rs12662670 1.14 0.019
" rs9397435 G " " " rs12665607 1.08 0.51
" rs9397435 G " " " rs9383589 0.99 0.95
" rs9397435 G " " " rs3734805 1.11 0.34
" rs9397435 G " " " rs6929137 1.14 3.9610
23
" rs9397435 G " " " rs2046210 1.14 6.1610
23
" rs9383932 G 0.132 1.06 0.066 rs9397435 1.00 0.91
" rs12662670 G 0.071 1.12 6.4610
23 rs9397435 1.00 0.96
" rs12665607 A 0.072 1.14 1.1610
23 rs9397435 1.04 0.69
" rs9383589 G 0.070 1.15 6.2610
24 rs9397435 1.13 0.22
" rs3734805 C 0.072 1.13 1.8610
23 rs9397435 1.02 0.87
" rs6929137 A 0.316 1.04 0.082 rs9397435 1.01 0.58
" rs2046210 T 0.337 1.04 0.099 rs9397435 1.02 0.41
Nigerian rs9397435 G 0.063 1.39 0.016 rs12662670 1.34 0.047
" rs9397435 G " " " rs12665607 1.32 0.068
" rs9397435 G " " " rs9383589 1.31 0.11
" rs9397435 G " " " rs3734805 1.43 0.049
" rs9397435 G " " " rs6929137 1.39 0.019
" rs9397435 G " " " rs2046210 1.44 0.047
" rs12662670 G 0.027 1.36 0.16 rs9397435 1.17 0.51
" rs12665607 A 0.010 1.76 0.079 rs9397435 1.33 0.43
" rs9383589 G 0.016 1.66 0.045 rs9397435 1.31 0.37
" rs3734805 C 0.028 1.33 0.16 rs9397435 0.94 0.82
" rs6929137 A 0.538 0.97 0.67 rs9397435 0.95 0.56
" rs2046210 T 0.716 1.00 0.96 rs9397435 0.91 0.73
Taiwanese rs9397435 G 0.326 1.23 8.0610
24 rs9383932 1.11 0.31
" rs9397435 G " " " rs12662670 1.18 0.12
" rs9397435 G " " " rs12665607 0.94 0.89
" rs9397435 G " " " rs9383589 1.54 0.028
" rs9397435 G " " " rs3734805 1.48 0.061
" rs9397435 G " " " rs6929137 1.73 8.4610
24
" rs9397435 G " " " rs2046210 1.11 0.21
" rs9383932 G 0.378 1.25 2.9610
24 rs9397435 1.14 0.21
" rs12662670 G 0.300 1.22 2.5610
23 rs9397435 1.06 0.59
" rs12665607 A 0.323 1.24 6.2610
24 rs9397435 1.31 0.52
" rs9383589 G 0.323 1.20 4.2610
23 rs9397435 0.79 0.24
" rs3734805 C 0.324 1.22 2.0610
23 rs9397435 0.83 0.37
" rs6929137 A 0.348 1.15 0.025 rs9397435 0.7 0.027
" rs2046210 T 0.363 1.24 4.3610
24 rs9397435 1.11 0.46
doi:10.1371/journal.pgen.1001029.t002
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protective effect of rs6929137[A] when adjusted for rs9397435 in
Asians. This is most likely to be due to a fluctuation in the data
since there is no sign of the effect in the other ancestries and there
were no quality issues with the genotyping of rs6929137.
The pattern of risk associations was further illuminated by an
examination of the common haplotypes generated by the typed
SNPs (Table 3). In the Nigerians, the rs9397435[G] allele is present
on several different, quite rare haplotypes (haplotypes E–I). All
except one (haplotype G) have OR point estimates greater than 1.
Two of these haplotypes (H and I) are more common in Europeans
and Asians than in Nigerians, and are the dominant at-risk
haplotypes in those population samples. Conversely, haplotypes E–
G are vanishingly rare in Europeans and Asians. In Nigerians, the
rs2046210[T] allele is present on all of the common haplotypes
carrying rs9397435[G] (haplotypes E–I). However it is also present
on two very common, non-risk haplotypes (A and B) and this
effectivelyattenuatesthe association ofrs2046210[T]withdiseasein
Nigerians. In Europeans, haplotype B is lower in frequency but
haplotype A is still present at substantial frequencies, again
attenuating an association of rs2046210[T] with breast cancer. In
Asians, haplotypes A and B are both very much lower in frequency
while the at-risk haplotype H has become the dominant haplotype
carrying rs2046210[T]. This illustrates how rs2046210[T] can be
strongly associated with risk in Chinese, but only weakly if at all in
the Europeans and Nigerians.
To increase the resolution of the haplotype analysis, we
generated a phylogenetic network based on HapMap data for
81 SNPs in the region (Figure S4). This confirmed that the
haplotype group H forms a contiguous branch with much greater
frequencies in Asians than in Africans. It also showed that the risk
allele rs9397435[G] is present on a diversity of haplotype
backgrounds in Africans, of which only some derivatives are
represented in Europeans and Asians. Given the dispersion of the
African haplotypes containing rs9397435[G], and assuming that
all haplotypes carrying this allele indeed confer risk, there does not
appear to be any HapMap SNP that could show a stronger
association. We did note however that haplotype G, the only
common haplotype for which we did not observe an OR point
estimate greater than 1, is in an ancestral position in the group H
branch of the network. This raises the possibility that the causative
variant arose after the mutation event that created rs9397435.
We examined the genomic region containing the 6–7%
European MAF class SNPs for correlations between SNP locations
and known functional features. The SNPs occur in a region
containing a number of ligand-inducible ER binding sites,
suggesting that this area may be involved in autoregulation of
the ESR1 gene [20,21]. However none of the SNPs in the 6–7%
MAF group (including the ungenotyped ones) actually mapped
within the identified ER binding sites. We noted that rs9397435 is
located at a site of histone modification marks in human
mammary epithelial cells (HMEC) and normal human keratino-
cytes (NHEK) that were experimentally verified by ChIP-Seq
methodology [22]. Peaks of H3K4me1 and H3K4me2 (but not
H3K4me3) co-localized with rs9397435. A moderate peak of
H3K9ac was also seen at this location in HMEC. This pattern of
histone modification has been associated with transcriptional
enhancers but not with transcription initiation sites [23]. None of
the other HapMap SNPs in the 6–7% MAF group showed similar
associations with histone modification peaks or any other notable
bioinformatic features.
To search for additional candidate causative variants, we
accessed the April 2009 release of the 1000 Genomes project
that includes data on 57 European individuals, 56 Yorubas and
59 Japanese or Han Chinese. We then looked for non-HapMap
SNPs that are well correlated (r
2$0.75) with rs9397435 in both
Europeans and Asians (no SNP was this highly correlated with
rs9397435 in Yorubas). We identified 10 non-HapMap SNPs
having this property of which 8 were listed in dbSNP build 130
and 2 were novel (Table S4). This list may not be exhaustive
because the data originate from a draft release from the 1000
Genomes project. Nevertheless, t h eS N P st h a tw e r ei d e n t i f i e d
must be considered as potential causative variants. We searched
for correlations between these 10 additional SNPs and locations
of known functional features. Ap r e v i o u s l yu n k n o w nC / TS N P
at position 152,010,891 was seen to coincide with a ChIP-SEQ
verified binding site of the transcriptional insulator protein
CTCF in a variety of cell types including HMEC [24]. The
variant changes a CpG sequence to TpG, the latter being
correlated (r
2=1 in CEU) with the rs9397435[G] breast cancer
Table 3. Frequencies of common haplotypes in European, African, and Asian ancestry population samples.
Nigeria Iceland U.S.A. European Ancestry Taiwan
Haplotype
a
Haplotype
ID
Frequency
in Cases
Frequency
in Controls
Frequency
in Cases
Frequency
in Controls
Frequency
in Cases
Frequency
in Controls
Frequency
in Cases
Frequency
in Controls
TAAATTA A 0.346 0.368 0.225 0.232 0.239 0.233 0.012 0.018
TGAATTA B 0.263 0.276 0.018 0.022 0.026 0.025 0.024 0.024
TGAATCA C 0.164 0.158 0.673 0.679 0.635 0.646 0.550 0.590
TAAATCA D 0.120 0.127 0.004 0.000 0.006 0.007 0.001 0.005
TGAATTG E 0.028 0.015 0.000 0.000 0.002 0.000 0.001 0.000
TAAATTG F 0.023 0.014 0.000 0.000 0.000 0.000 0.000 0.001
TACATTG G 0.011 0.013 0.000 0.000 0.000 0.000 0.000 0.000
GACGATG H 0.015 0.009 0.065 0.053 0.067 0.059 0.304 0.260
TACGATG I 0.000 0.000 0.007 0.004 0.009 0.008 0.049 0.036
GGAATCA J 0.000 0.000 0.006 0.004 0.004 0.007 0.023 0.023
aThe SNPs and at-risk alleles are ordered as: rs12662670_G, rs6929137_A, rs3734805_C, rs9383589_G, rs12665607_A, rs2046210_T, rs9397435_G. Haplotypes with an
observed control frequency of $0.01 in any one of the population samples are included.
doi:10.1371/journal.pgen.1001029.t003
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methylation of CpG sites, we investigated the novel C/T SNP at
152,010,891 in more detail. We confirmed its existence by
Sanger sequencing a sample of Europeans and generated a
single-track Centaurus assay for it. The SNP is now listed as
rs77275268 in dbSNP build 131. We confirmed its LD relations
with rs9397435 in samples of European and Chinese ancestry
(Table S5). We also found that rs77275268 exists in Africans at
a MAF of 1.3% (in controls) and is most closely correlated there
with rs9383589 among the typed HapMap SNPs (Table S5).
Like rs9383589, it showed a nominally significant association
with breast cancer in the African ancestry samples (OR=1.97,
P=7.4 610
23). Bisulfite sequencing of peripheral blood DNA
from 29 European individuals who were CC homozygotes for
rs77275268 showed that the CpG sequence is partially
methylated (Figure S5). The occurrence of the TpG variant at
this position thus precludes facultative methylation and may
affect CTCF binding.
To investigate a possible impact of the risk variants on gene
expression, levels of ESR1, progesterone receptor (PGR)a n d
HER2 (ERBB2) mRNAs were assessed in 1,234 frozen tumour
samples (see Materials and Methods). SNP rs9397435 was
genotyped using DNA samples from the same tumours. The
at-risk GG homozygotes expressed mean levels of ESR1 and
PGR mRNA that were four to five-fold higher than the levels in
AA homozygotes and AG heterozygotes (Figure S6). When
assessed under our default, multiplicative (co-dominant) inher-
itance model, these differences were of borderline significance
for PGR and not significant for ESR1 (Table S6). Assessed under
a recessive inheritance model, the increases in both ESR1 and
PGR mRNA levels in GG homozygotes were significant
(P=0.024 and 0.031 for ESR1 and PGR respectively, (Table
S6)). In comparisons with the full genotype model, neither the
multiplicative nor the recessive models could be rejected.
ERBB2 mRNA levels did not vary with genotype. These
findings raise the possibility that rs9397435[G] (or a correlated
SNP) might act to increase expression of ESR1 and, as a
consequence, increase PGR expression. However, we caution
that these findings should be considered only as hypothesis-
generating since the GG homozygotes are rare and the
significance is marginal. Moreover, we saw no evidence that
the association between rs9397435[G] and breast cancer risk per
se showed a recessive pattern of inheritance (P=0.75 and 0.93
for a test of the multiplicative vs the full genotype model in
Europeans and Taiwanese respectively).
We reviewed the medical records of approximately 8,441
European and Taiwanese patients, including 1,792 from a series
of case-only cohorts. The rs9397435[G] allele was found to
confer significant risk of both ER positive and ER negative breast
cancer and of both progesterone receptor positive and negative
disease (Table S7, Table S8). These results were puzzling in light
of the proximity of the risk variant to the ESR1 gene and the
putative effect of rs9397435[G] homozygosity on gene expression
described above. However the observed association with both ER
positive and ER negative disease is in agreement with Zheng
et al., who reported significant associations with both ER positive
and ER negative breast cancer in Chinese women, with a higher
OR for ER negative breast cancer than for ER positive disease
[1]. Clearly, the phenotypic effect of the risk variant merits
further investigation. In Europeans, we observed that
rs9397435[G] was associated at nominal significance with an
earlier age at first invasive breast cancer (P=0.015, Table S7),
although this effect was not evident in the Taiwanese patient
sample (Table S8).
Discussion
In summary, we have shown that the initially reported [1]
Chinese breast cancer risk variant rs2046210 cannot be effectively
used as a risk marker in Europeans and Africans because it does
not tag the causative variant(s) in all three ancestries. We have
identified a variant, rs9397435[G], that confers risk of breast
cancer with a consistent effect in all three main ancestral
populations and that can fully explain the association signal in
each population. The frequency of the rs9397435[G] risk allele is
substantially lower in Europeans and Africans (6.3% in controls)
than it is in Taiwanese (32.6%). This limits the power to detect an
effect of this variant with confidence even in a large sample of
Europeans as was used here. It may also explain why the variant
was not detected in previous genome-wide association studies
conducted in Europeans [4,17], even though the class was
reasonably well tagged on the Illumina chips used (Figure 2).
In addition to rs9397435, three other HapMap SNPs
rs12665607, rs9383589, and rs3734805 are consistently associated
with risk in all three ancestries and cannot be distinguished from
rs9397435 based on the currently available data. This highlights
the fact that, in general, the resolution of fine mapping is very
sensitive to power restrictions. For example, inspection of the
haplotype distribution (Table 3) suggests that, given a sufficiently
large sample of Chinese, it might be possible to resolve haplotypes
A and B from haplotypes H and I (thereby resolving rs2046210
from rs9397435) in this ancestral group alone. As we have shown,
shifting the analysis between ancestries can provide some
additional resolution without resorting to very large sample sizes.
It can also be seen (Figure 2B) that the greatest potential resolution
is offered by Africans, populations where the collection of large
samples is challenging. Naturally, the ancestry shift approach is
only viable if the variant arose before population divergence and
even if the variant is present in multiple ancestral populations, the
optimum strategy can vary from locus to locus [25].
Haplotypeanalysisconductedby[1]indicatedthatrs2046210[T]
is present on multiple at-risk haplotypes, consistent with the
presence of a single, common causative variant highly correlated
withrs2046210in Chinese. Howeveran observed association with a
common SNP can also arise from a set of multiple underlying
pathogenic variants [26]. In this study we do not make the
presumption of a single underlying causative variant, although for
simplicity we refer to a single variant. Under the single variant
hypothesis, refinement mapping will identify SNPs closely correlat-
ed with the causative variant and the causative variant itself is
expected to be one of those variants which give the strongest
association signals. Under a multiple pathogenic variant hypothesis,
refinement mapping will identify SNPs that tag the set better
(although one might expect it to be more difficult to identify SNPs
that show homogeneity of effect between ancestral groups).
However in this case the group of tagging SNPs giving the strongest
signals will not necessarily contain pathogenic variants. For some
practical purposes, such as genetic risk assessment, distinction
between the two hypotheses may not be important, but the
difference is crucial if the aim is to identify the underlying
pathogenic genetic lesion(s). An example is seen in the LOXL1
locus where two nonsynonymous SNPs, thought to be pathogenic
variants, account for an association with exfoliation glaucoma. The
strongest association in the GWAS arose from a third SNP
(rs2165241) that is in LD with both nonsynonymous variants [27].
In this study we have presented evidence that both rs9397435 and
rs77275268 are located at sites of potential functional significance.
While these SNPs merit further investigation, we note that in the
absence of conclusive evidence of a single underlying causative
Ancestry and C6orf97-ESR1
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SNPs highly correlated with rs9397435 in Asians and Europeans.
Materials and Methods
Ethics statement
This work was approved by the National Bioethics Committee
of Iceland and the Icelandic Data Protection Authority and by the
respective local review boards for the samples provided by external
collaborators.
Samples
The breast cancer case:control population samples are listed
and referenced in Table S1. The Netherlands (Rotterdam) case-
only DNA samples were isolated from 1,792 frozen tumour
specimens. Only primary tumours were used and none of the
patients had received neo-adjuvant treatment. The year of surgery
was between 1978 and 2002. The patients’ ages ranged from 22
through 88 years at diagnosis. 1748 patients were M0 at diagnosis,
while 44 showed metastatic disease (M1). 1100 patients had lymph
node negative disease, 676 were diagnosed with involved lymph
nodes and for 16 patients this information was missing. ER was
determined in 1783 tumours, 453 were negative (,10 fmol/mg
protein) and 1330 were positive. Further details of these patient
cohorts have been published previously [28,29].
The U.S.A. (Chicago) samples were from individuals of self-
reported African American ancestry, drawn from the Chicago
Cancer Prone Study (CCPS), which is an ongoing hospital-based
case:control investigation designed to study the genetics of breast
cancer in young patients. Cases with histologically confirmed
breast cancer were enrolled through the Cancer Risk Clinic at the
University of Chicago. Early-onset cases and African Americans
were oversampled. Controls without breast cancer were gender
and age-matched with cases and enrolled from patients who visit
the same hospital and are wiling to donate blood for genetic
studies. Similar to the Nigerian Breast Cancer Study, the CCPS
adopted the questionnaire of the Breast Cancer Family Registry.
Blood samples were collected from cases and controls and used for
DNA isolation. Pathological and clinical data were collected for
cases. The study is associated with the University of Chicago
Specialized Program of Research Excellence (SPORE) pro-
gramme.
Genotyping
Genotyping was carried out using Nanogen Centaurus assays
[18]. Assays were validated by genotyping on HapMap CEU, YRI
and CHB/JPT samples and comparing the genotypes with the
published data. Assays were rejected if they showed $1.5%
mismatches with the HapMap data. Genotyping of Icelandic and
foreign samples was carried out at the deCODE Genetics facility.
Clustering algorithms were applied and manual editing was
carried out in a standardized manner for all sample sets. Two
standard control DNA samples and water blanks were included on
every plate. Genotyping yields were in excess of 98% for all SNP-
Sample combinations attempted.
Bisulfite sequencing. Bisulfite treatment of 1 mg of each
peripheral blood DNA sample was conducted with EpiTect
Bisulfite Kit (QIAGEN-59104) according to the manufacturer’s
protocol. PCR and Sanger sequencing was conducted with
standard protocols.
Gene expression analysis
RNA isolation and quantitative RT-PCR analysis was carried
out as described previously [30]. Briefly, tumour material was
preserved in liquid nitrogen and RNA isolated from 20–60
cryostat sections of 30mm using standard methods. cDNA was
synthesized using oligo (dT) and random hexamer primers. Real-
time quantitative PCR was done on an ABI Prism 7700 Sequence
Detection System (Applied Biosystems) using assay primers
described in [30,31]. Ct values for the target genes were
normalized to the mean Ct values of three housekeeping genes
(HMBS, HPRT and B2M) and expressed as: Relative Expression
Level=2
(mean Ct housekeeping2mean Ct target).
Statistical analysis
To construct dendrograms, SNPs were arranged in hierarchical
clusters based on the r
2 relationships between them. The clustering
was performed using the ‘‘stats’’ package of R software. The
‘‘hclust’’ command was used with the method ‘‘average’’. Pairwise
r
2 values were first re-arranged into a bi-dimensional matrix M
that was transformed into a similarity matrix by performing the
operation 1-M. The similarity matrix obtained was finally used as
a distance matrix and depicted by a dendrogram. In this similarity
matrix an original r
2 value of 1 is thus transformed to 0,
representing a distance of 0 from a fully correlated SNP.
We calculated the OR for each SNP allele assuming the
multiplicative model, i.e. assuming that the relative risk to a person
is the product of the relative risks of each of the two alleles carried.
This assumption was tested by calculating genotype-specific
relative risks for each SNP in Europeans and comparing them to
those determined under the multiplicative model. No significant
deviations from the multiplicative model were observed. There-
fore, allelic OR and P values are presented in the data tables. P
values were calculated with the standard likelihood ratio x
2
statistic and confidence intervals were calculated assuming that the
estimate of OR has a log-normal distribution. Some Icelandic
cases and controls are related to each other, causing the x
2 statistic
to have a mean .1. We estimated the inflation factor using a
previously described procedure in which genotypes were simulated
through the genealogy of 731,175 Icelanders and the x
2 corrected
statistics accordingly [32]. The inflation factor for the set of
Icelandic samples used in this study was 1.08 and all P values cited
have been adjusted accordingly. Individuals in the replication
sample sets were assumed to be unrelated to each other. In this
study we did not carry out a comprehensive scan of the region in
Europeans. Rather, we tested a specific hypothesis; i.e. whether
any of the European equivalence classes that correspond to the
Asian equivalence class of rs2046210, confer risk of breast cancer
in Europeans. The appropriate multiple testing adjustment
therefore takes into consideration the number of equivalence
classes tested in each ancestry.
The tested SNPs are in LD with each other. Therefore,
wherever the genotype of one SNP was missing for an individual,
the genotypes of the correlated SNPs were used to infer the
missing genotypes using a likelihood approach as described
previously [33]. This ensured that the same set of individuals is
tested for each SNP. Thus, all P values are based on the same
individuals, making comparisons more straightforward. Joint
analyses of multiple case:control replication groups was carried
out using a Mantel-Haenszel model in which the groups are
allowed to have different population allele frequencies but were
assumed to have common relative risks. This was done when
combining the various European sample sets, when combining the
Nigerians and African Americans, and when combining samples of
different ancestries. Tests of heterogeneity were performed by
comparing the null hypothesis of the effect being the same in all
populations to the alternative hypothesis of each population
having a different effect using a likelihood ratio test. I
2 takes values
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variation in estimates that is due to heterogeneity [34].
Haplotype frequencies using the genotyped SNPs were
estimated by maximum likelihood using the haplotype analysis
program NEMO [35]. For the haplotype analysis using HapMap
data, phased haplotypes were generated for the 60 CEU parents,
60 YRI parents and 90 Asian individuals. The phases of alleles in
haplotypes was estimated using the EM algorithm, in combination
with the family trio information for the CEU and YRI groups
(where the genotypes from the 30 children were used to help infer
the allelic phase of the haplotypes).
Quantitative RT-PCR data were analyzed under the multipli-
cative model by regressing log10 transformed Relative Expression
Level values against the number of risk alleles carried (0,1,2).
When testing the recessive model, we used the GG homozygote
status as an explanatory variable taking values 0 (AA homozygote
or AG heterozygote) or 1 (GG homozygote). In the full model, we
used two explanatory variables; the AG heterozygote status (0 or 1)
and the GG homozygote status (0 or 1).
Bioinformatics
For the list of candidate SNPs we carried out a search for
overlaps between SNP position and known bioinformatic features.
We retrieved data from the UCSC human genome browser and
from the UCSC test browser (HG18 build 36) [36]. We also
retrieved data from three bioinformatic feature publications
[20,21,37]. We accessed all available feature tracks containing
genome positional information (approximately 10,000 tracks) and
identified those features that overlapped with SNPs. Data from the
1000 Genomes project were obtained from the April 2009 release
(http://www.1000genomes.org). These are recognized draft
quality data and were used as is without quality filtering. All
genomic locations quoted are from HG18 build 36.
Supporting Information
Figure S1 Overview of LD at the C6orf97-ESR1 locus. The
figure shows a view of the genomic region of chromosome 6,
nucleotides 151,930,000–152,200,000 taken from the UCSC
browser Build 36 assembly (hg18). The track ‘‘Eq class SNPs’’
shows the locations of the SNPs that are correlated (r
2.0.65) with
rs2046210 in Han Chinese. The C6orf97 and the four RefSeq
isoforms of ESR1 are shown. Below that are LD plots of D9 (a) and
r
2 (b) between pairs of SNPs in the region. Darker shading
indicates stronger LD values. Data are based on phased genotypes
from HapMap Phase II release 22.
Found at: doi:10.1371/journal.pgen.1001029.s001 (0.22 MB
DOC)
Figure S2 Dendrogram showing r
2 relationships between
C6orf97-ESR1 SNPs in HapMap Han Chinese (CHB). On the
left are listed the SNPs that are correlated with an r
2.0.65 with
rs2046210. The SNPs are arranged in a hierarchical cluster
dendrogram based on the r
2 values between them derived from the
HapMap Phase II release 23a genotypes. Note that the scale on
the top of the panel shows 1-r
2 values (i.e. a value of 0 corresponds
to an r
2 of 1). The scale is limited in range because the SNPs were
selected to have r
2 values greater than 0.65.
Found at: doi:10.1371/journal.pgen.1001029.s002 (0.91 MB
DOC)
Figure S3 Dendrograms showing r
2 relationships between the
C6orf9-ESR1 SNPs genotyped in each study population. On the
left are listed the SNPs that were genotyped in each of the study
population samples. The name of the study population sample is
indicated on the right of each panel. The SNPs are arranged in a
hierarchical cluster dendrogram based on the r
2 values between
them derived from the observed genotypes for the SNPs. Note that
the scales on the top of the panels show 1-r
2 values (i.e. a value of 0
corresponds to an r
2 of 1). The scale for the Taiwanese sample is
limited in range between 0 and 0.4 (corresponding to an r
2 range
of 1 to 0.6) because all genotyped SNPs had r
2 values greater than
0.6. The scale for the USA, African-American ancestry and the
Nigerians ranges from 0.3 to 1.0 (corresponding to an r
2 range of
0.7 to 0) because no pair of genotyped SNPs had r
2 values between
them of greater than 0.7.
Found at: doi:10.1371/journal.pgen.1001029.s003 (2.35 MB
DOC)
Figure S4 Haplotype analysis of the C6orf97-ESR1 region. Shown
is a median joining (MJ) network describing the evolutionary
relationships between haplotypes inferred from the genotypes of 81
HapMap (Phase II release 21) SNPs in the region chr6:151,
950,821–151,992,990. Each haplotype is represented by a circle
whose area reflects the overall number of copies observed and
whose colour coding indicates the frequency of the haplotype in the
different ancestral groups as indicated in the figure. Lines between
the circles represent mutational evolutionary pathways between
haplotypes reconstructed by the MJ algorithm. The line length is
proportional to the number of inferred mutational differences
between haplotypes. Black nodes represent non-sampled haplotypes
that were reconstructed by the MJ algorithm as evolutionary
intermediates between observed haplotypes. Encircled clusters of
haplotypes are those carrying the rs9397435[G] allele and their
lettering corresponds to the haplotype IDs shown in Table 3.
Haplotypes K and L contain the rs9397435[G] allele but were too
rare to qualify for inclusion in Table 3. Note that in Asians and
Europeans, haplotypes bearing rs9397435[G] are clustered on the
H, I and L branches, whereas in Yorubas the rs9397435[G] allele is
found on more widely dispersed branches. Note also that Haplotype
G, which was observed only in Yorubas, is in an ancestral position
on the main H,I,L branch.
Found at: doi:10.1371/journal.pgen.1001029.s004 (0.14 MB
DOC)
Figure S5 Bisulfite sequencing of region surrounding the C/T
SNP at position 152,010,891 (arrowed) showing differential
methylation of the C nucleotide in CC homozygotes. The top line
shows the reference (non-bisulfite treated) sequence. Panels a–d
show sequence traces of bisulfite-treated DNA from four CC
homozygous individuals. In samples a and b the C nucleotide is
predominantly methylated while a minority is unmethylated. In
sample c, the C is predominantly unmethylated and in sample d
similar amounts of methylated and unmethylated C are present. At
neighboring C nucleotides, the conversion of unmethylated cytosine
is complete, indicating that the bisulfite treatment was effective. In
addition, we noted that nearby CpGs at positions 152,010,768,
152,010,842, 152,010,940, 152,011,003 and 152,011,013 were also
methylated or partially methylated.
Found at: doi:10.1371/journal.pgen.1001029.s005 (0.43 MB
DOC)
Figure S6 Quantitative RT-PCR analysis of ESR1 (ER), PGR (PG)
and ERBB2 (HER2) mRNAs in tumours with different genotypes for
rs9397435. RNA and DNA was isolated from 1,234 frozen tumour
specimens. RNA levels were analyzed by RT-PCR and normalized
to the mean level of three housekeeping genes. Relative expression
levels are calculated as 2
(mean Ct housekeeping2mean Ct target). Genotypes
of rs9397435 were determined by Centaurus assay. Numbers of
individuals with each genotype are 1,072 (AA), 151 (AG) and 11
(GG). Histogram displays the mean relative expression level
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mean of log10 of relative expression level)f o re a c hg e n o t y p e .
Error bars indicate the standard error of the mean relative expression
levels.
Found at: doi:10.1371/journal.pgen.1001029.s006 (0.05 MB
DOC)
Table S1 Overview of the sample sets used in the study.
Found at: doi:10.1371/journal.pgen.1001029.s007 (0.05 MB
DOC)
Table S2 Association of C6orf97/ESR1 SNPs with breast cancer
in each population sample.
Found at: doi:10.1371/journal.pgen.1001029.s008 (0.20 MB
DOC)
Table S3 Heterogeneity in risk estimates for combined popula-
tion samples.
Found at: doi:10.1371/journal.pgen.1001029.s009 (0.06 MB
DOC)
Table S4 Non-HapMap SNPs in strong LD with rs9397435
identified from 1,000 Genomes Project Data
a.
Found at: doi:10.1371/journal.pgen.1001029.s010 (0.05 MB
DOC)
Table S5 LD relations with the novel chr6:152,010,891[C/T]
SNP (rs77275268).
Found at: doi:10.1371/journal.pgen.1001029.s011 (0.04 MB
DOC)
Table S6 Levels of ERa, PR, and HER2 mRNA in primary
tumours, stratified by rs9397435 genotype and assessed under
multiplicative and recessive inheritance models.
Found at: doi:10.1371/journal.pgen.1001029.s012 (0.05 MB
DOC)
Table S7 Stratification by clinical variables of breast cancer
associations with rs9397435[G] in combined European ancestry
population samples
a.
Found at: doi:10.1371/journal.pgen.1001029.s013 (0.11 MB
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